What is it about?
The next generation of medical imaging technology combines MRI and PET, but new imaging agents are required to optimally exploit both technologies and to enhance early detection of diseases. We used a simple one-pot strategy to label nanoparticles with both an imaging label for MRI and radioiodine for nuclear medicine. As radioiodine can also be used to treat tumours, next to diagnosis the particle could potentially also be used for theranostics.
Featured Image
Why is it important?
An early accurate diagnosis of a disease is essential to improve the chance of a successful treatment outcome using a patient-specific treatment protocol. Multimodality imaging instruments combine the advantages of each modality, for example combining anatomical information (MRI) with a high sensitivity (PET). A multimodal imaging agent is a prerequisite to optimally and cost-effective exploit these benefits.
Perspectives
It has been great to collaborate with other Australian institutions like ANSTO and the Melbourne Brain Centre; and combining our knowledge in nanomedicine, radiochemistry and MRI. I hope our work will one day contribute to an earlier diagnosis of diseases and a better outcome for patients.
Dr Lars Esser
CSIRO
Read the Original
This page is a summary of: A tunable one-pot three-component synthesis of an125I and Gd-labelled star polymer nanoparticle for hybrid imaging with MRI and nuclear medicine, Polymer Chemistry, January 2018, Royal Society of Chemistry,
DOI: 10.1039/c8py00621k.
You can read the full text:
Contributors
The following have contributed to this page
